We are analyzing https://link.springer.com/article/10.1007/s40495-025-00405-2.

Title:
Mitochondria for Cardiovascular Therapy: A Deep Dive into Drug Targets and Therapeutic Approaches | Current Pharmacology Reports
Description:
Purpose Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide. Mitochondria are central to cardiac physiology, governing energy production, redox signaling, calcium homeostasis, and metabolic adaptation. Given their crucial role, mitochondrial dysfunction is increasingly recognized as a fundamental contributor to CVD progression. This review aims to provide an updated perspective on mitochondrial involvement in cardiovascular health and disease, emphasizing recent therapeutic advances and potential clinical applications. Recent Findings Mitochondrial dysfunction has been implicated in the pathogenesis of various CVDs, including heart failure, myocardial infarction, and ischemia–reperfusion (I/R) injury. Advances in mitochondrial-targeted drug development have identified novel therapeutic strategies, such as modulation of mitochondrial bioenergetics, dynamics, quality control, and signaling pathways. Additionally, emerging research has expanded our understanding of mitophagy, mitochondrial transfer therapies, and the role of mitochondrial-derived signals in cardiac pathophysiology. Conclusion Targeting mitochondrial pathways represents a promising therapeutic approach for managing CVDs. However, key challenges remain, including efficient drug delivery, off-target effects, and interpatient variability in response to mitochondrial interventions. This review not only explores these approches but also summarizes compounds currently in preclinical and clinical stages that directly affect mitochondrial function. Additionally, we discuss novel strategies, such as mitochondrial transplantation and advanced drug delivery systems, that may enhance therapeutic efficacy. A deeper understanding of mitochondrial biology and its systemic interactions will be essential for translating these innovations into effective clinical treatments for cardiovascular diseases. Graphical Abstract Treatment can impact on different mitochondrial functions in CVDs
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

pubmed, article, google, scholar, cas, mitochondrial, central, heart, cell, cardiovascular, function, therapeutic, cardiac, failure, liu, disease, injury, httpsdoiorgs, med, mol, diseases, wang, mitochondria, dysfunction, biol, improves, drug, calcium, treatment, zhang, cardiol, chen, pharmacol, role, myocardial, targeting, transplantation, sci, cardiomyopathy, cardiovasc, patients, access, res, death, privacy, cookies, content, data, research, current,

Topics {✒️}

month download article/chapter mitochondria-targeting hydrogen sulfide mitochondria-targeted drug delivery dorn gw 2nd exosomes-mediated drug delivery mitochondria-targeted plastoquinone derivatives mitochondrial-targeted drug development mitochondrial-targeted antioxidant supplementation mitochondrial ca2+ uptake mitochondria-targeting peptide bendavia cardiovasc pharmacol therapeutics age-related diseases full article pdf mitochondrial quality control reactive oxygen species cardiac physiology improves cardiac lusitropy mitochondrial fusion reveals heart failure induced accepted manuscript version improves left ventricular small-molecule inhibitor mitochondrial permeability transition privacy choices/manage cookies ischemia-reperfusion injury left ventricular dysfunction mitochondria-targeting peptide article semenzato autologous mitochondrial transplantation cardiac microvascular injury small molecule activators vascular endothelial injury diabetic endothelial dysfunction single cardiac myocytes additional information publisher' early reperfusion injury ischaemia/reperfusion injury american heart association mitochondrial-derived signals attenuates mitochondrial abnormalities ampk/ucp2 pathway mitochondrial calcium signalling phase 2a trial mitophagy-promoting agents ischemic tissue damage mitochondrial dynamics deborah naón mitochondrial transfer therapies left ventricular function cardiovascular diseases

Questions {❓}

L-carnitine, a friend or foe for cardiovascular disease?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Mitochondria for Cardiovascular Therapy: A Deep Dive into Drug Targets and Therapeutic Approaches
         description:Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide. Mitochondria are central to cardiac physiology, governing energy production, redox signaling, calcium homeostasis, and metabolic adaptation. Given their crucial role, mitochondrial dysfunction is increasingly recognized as a fundamental contributor to CVD progression. This review aims to provide an updated perspective on mitochondrial involvement in cardiovascular health and disease, emphasizing recent therapeutic advances and potential clinical applications. Mitochondrial dysfunction has been implicated in the pathogenesis of various CVDs, including heart failure, myocardial infarction, and ischemia–reperfusion (I/R) injury. Advances in mitochondrial-targeted drug development have identified novel therapeutic strategies, such as modulation of mitochondrial bioenergetics, dynamics, quality control, and signaling pathways. Additionally, emerging research has expanded our understanding of mitophagy, mitochondrial transfer therapies, and the role of mitochondrial-derived signals in cardiac pathophysiology. Targeting mitochondrial pathways represents a promising therapeutic approach for managing CVDs. However, key challenges remain, including efficient drug delivery, off-target effects, and interpatient variability in response to mitochondrial interventions. This review not only explores these approches but also summarizes compounds currently in preclinical and clinical stages that directly affect mitochondrial function. Additionally, we discuss novel strategies, such as mitochondrial transplantation and advanced drug delivery systems, that may enhance therapeutic efficacy. A deeper understanding of mitochondrial biology and its systemic interactions will be essential for translating these innovations into effective clinical treatments for cardiovascular diseases. Treatment can impact on different mitochondrial functions in CVDs
         datePublished:2025-04-04T00:00:00Z
         dateModified:2025-04-04T00:00:00Z
         pageStart:1
         pageEnd:15
         sameAs:https://doi.org/10.1007/s40495-025-00405-2
         keywords:
            Cardiovascular diseases
            Mitochondrial dysfunction
            Targeted delivery
            Mitochondrial dynamics
            Mitophagy
            Mitochondrial transplantation
            Pharmacology/Toxicology
            Biomedicine
            general
            Cancer Research
            Molecular Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40495-025-00405-2/MediaObjects/40495_2025_405_Figa_HTML.png
         isPartOf:
            name:Current Pharmacology Reports
            issn:
               2198-641X
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Martina Semenzato
               url:http://orcid.org/0000-0003-2232-0921
               affiliation:
                     name:University of Padua
                     address:
                        name:Department of Biology, University of Padua, Padua, Italy
                        type:PostalAddress
                     type:Organization
                     name:Veneto Institute of Molecular Medicine (VIMM)
                     address:
                        name:Veneto Institute of Molecular Medicine (VIMM), Padua, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Deborah Naón
               url:http://orcid.org/0000-0002-9726-4664
               affiliation:
                     name:Institute for Research in Biomedicine (IRB Barcelona)
                     address:
                        name:Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
                        type:PostalAddress
                     type:Organization
                     name:CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)
                     address:
                        name:CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Mitochondria for Cardiovascular Therapy: A Deep Dive into Drug Targets and Therapeutic Approaches
      description:Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide. Mitochondria are central to cardiac physiology, governing energy production, redox signaling, calcium homeostasis, and metabolic adaptation. Given their crucial role, mitochondrial dysfunction is increasingly recognized as a fundamental contributor to CVD progression. This review aims to provide an updated perspective on mitochondrial involvement in cardiovascular health and disease, emphasizing recent therapeutic advances and potential clinical applications. Mitochondrial dysfunction has been implicated in the pathogenesis of various CVDs, including heart failure, myocardial infarction, and ischemia–reperfusion (I/R) injury. Advances in mitochondrial-targeted drug development have identified novel therapeutic strategies, such as modulation of mitochondrial bioenergetics, dynamics, quality control, and signaling pathways. Additionally, emerging research has expanded our understanding of mitophagy, mitochondrial transfer therapies, and the role of mitochondrial-derived signals in cardiac pathophysiology. Targeting mitochondrial pathways represents a promising therapeutic approach for managing CVDs. However, key challenges remain, including efficient drug delivery, off-target effects, and interpatient variability in response to mitochondrial interventions. This review not only explores these approches but also summarizes compounds currently in preclinical and clinical stages that directly affect mitochondrial function. Additionally, we discuss novel strategies, such as mitochondrial transplantation and advanced drug delivery systems, that may enhance therapeutic efficacy. A deeper understanding of mitochondrial biology and its systemic interactions will be essential for translating these innovations into effective clinical treatments for cardiovascular diseases. Treatment can impact on different mitochondrial functions in CVDs
      datePublished:2025-04-04T00:00:00Z
      dateModified:2025-04-04T00:00:00Z
      pageStart:1
      pageEnd:15
      sameAs:https://doi.org/10.1007/s40495-025-00405-2
      keywords:
         Cardiovascular diseases
         Mitochondrial dysfunction
         Targeted delivery
         Mitochondrial dynamics
         Mitophagy
         Mitochondrial transplantation
         Pharmacology/Toxicology
         Biomedicine
         general
         Cancer Research
         Molecular Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40495-025-00405-2/MediaObjects/40495_2025_405_Figa_HTML.png
      isPartOf:
         name:Current Pharmacology Reports
         issn:
            2198-641X
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Martina Semenzato
            url:http://orcid.org/0000-0003-2232-0921
            affiliation:
                  name:University of Padua
                  address:
                     name:Department of Biology, University of Padua, Padua, Italy
                     type:PostalAddress
                  type:Organization
                  name:Veneto Institute of Molecular Medicine (VIMM)
                  address:
                     name:Veneto Institute of Molecular Medicine (VIMM), Padua, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Deborah Naón
            url:http://orcid.org/0000-0002-9726-4664
            affiliation:
                  name:Institute for Research in Biomedicine (IRB Barcelona)
                  address:
                     name:Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
                     type:PostalAddress
                  type:Organization
                  name:CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)
                  address:
                     name:CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Pharmacology Reports
      issn:
         2198-641X
      volumeNumber:11
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Padua
      address:
         name:Department of Biology, University of Padua, Padua, Italy
         type:PostalAddress
      name:Veneto Institute of Molecular Medicine (VIMM)
      address:
         name:Veneto Institute of Molecular Medicine (VIMM), Padua, Italy
         type:PostalAddress
      name:Institute for Research in Biomedicine (IRB Barcelona)
      address:
         name:Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
         type:PostalAddress
      name:CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)
      address:
         name:CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Martina Semenzato
      url:http://orcid.org/0000-0003-2232-0921
      affiliation:
            name:University of Padua
            address:
               name:Department of Biology, University of Padua, Padua, Italy
               type:PostalAddress
            type:Organization
            name:Veneto Institute of Molecular Medicine (VIMM)
            address:
               name:Veneto Institute of Molecular Medicine (VIMM), Padua, Italy
               type:PostalAddress
            type:Organization
      name:Deborah Naón
      url:http://orcid.org/0000-0002-9726-4664
      affiliation:
            name:Institute for Research in Biomedicine (IRB Barcelona)
            address:
               name:Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
               type:PostalAddress
            type:Organization
            name:CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)
            address:
               name:CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Biology, University of Padua, Padua, Italy
      name:Veneto Institute of Molecular Medicine (VIMM), Padua, Italy
      name:Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
      name:CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(375)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.59s.

LINK . SPRINGER . COM {}